Tocilizumab
Sarcoma,Soft Tissue
University of Southern Californiamonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Sarcoma,Soft Tissue cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
Adapt-001 EpicentRx, Inc. | Phase 2 | CCC |
Bcma/Gprc5D Car-T Cells Essen Biotech | Phase 1/2 | CCC |
Hbi 0201-Eso Tcrt Hadassah Medical Organization | Phase 1/2 | CCC |
Fludarabine Hadassah Medical Organization | Phase 1/2 | CCC |
cd146/her2 car-t cells Essen Biotech | Phase 1/2 | CCC |
Polyiclc University of Southern California | Phase 1 | CC |
Seclidemstat Salarius Pharmaceuticals, LLC | Phase 1 | CC |
Same molecule, other indications
Tocilizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →